FDA's Genomic Biomarker Qualification Guidance Lays Out Submissions Plan for Sponsors
August 24, 2011
FDA's Genomic Biomarker Qualification Guidance Lays Out Submissions Plan for Sponsors
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 9, 2013 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Dx Assays Launches Fee-for-Service CDx Development Initiative Giving Pharma More Control
November 2, 2012 / Pharmacogenomics Reporter - Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - Personalized Medicine in 2011: Some Successes, Slow Progress, Continued Economic Woes
January 4, 2012 / Pharmacogenomics Reporter